|
1
|
Peters S, Kerr KM and Stahel R: PD-1
blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat
Rev. 62:39–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gentzler R, Hall R, Kunk PR, Gaughan E,
Dillon P, Slingluff CL Jr and Rahma OE: Beyond melanoma: Inhibiting
the PD-1/PD-L1 pathway in solid tumors. Immunotherapy. 8:583–600.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Massari F, Santoni M, Ciccarese C, Santini
D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R,
Montironi R, et al: PD-1 blockade therapy in renal cell carcinoma:
Current studies and future promises. Cancer Treat Rev. 41:114–121.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Y, Wu L, Tian C and Zhang Y:
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Ann
Hematol. 97:229–237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou TC, Sankin AI, Porcelli SA, Perlin
DS, Schoenberg MP and Zang X: A review of the PD-1/PD-L1 checkpoint
in bladder cancer: From mediator of immune escape to target for
treatment. Urol Oncol. 35:14–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnson DB, Chandra S and Sosman JA:
Immune checkpoint inhibitor toxicity in 2018. JAMA. 320:1702–1703.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Balaji A, Verde F, Suresh K and Naidoo J:
Pneumonitis from anti-PD-1/PD-L1 therapy. Oncology (Williston
Park). 31:739–746. 2017.PubMed/NCBI
|
|
9
|
Ribas A, Puzanov I, Dummer R, Schadendorf
D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD,
et al: Pembrolizumab versus investigatorchoice chemotherapy for
ipilimumab-refractory melanoma (KEYNOTE-002): A randomised,
controlled, phase 2 trial. Lancet Oncol. 16:908–918. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced nonsmall-cell lung cancer (KEYNOTE-010): A
randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Robert C, Schachter J, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med.
372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weber JS, D'Angelo SP, Minor D, Hodi FS,
Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD,
et al: Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate
037): A randomised, controlled, open-label, phase 3 trial. Lancet
Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Barjaktarevic IZ, Qadir N, Suri A,
Santamauro JT and Stover D: Organizing pneumonia as a side effect
of ipilimumab treatment of melanoma. Chest. 143:858–861. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Naidoo J, Wang X, Woo KM, Iyriboz T,
Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin
AM, et al: Pneumonitis in patients treated with antiprogrammed
death-1/programmed death ligand 1 therapy. J Clin Oncol.
35:709–717. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iwanaga N and Kolls JK: Updates on T
helper type 17 immunity in respiratory disease. Immunology.
156:3–8. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Collison LW, Workman CJ, Kuo TT, Boyd K,
Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS and Vignali DA:
The inhibitory cytokine IL-35 contributes to regulatory T-cell
function. Nature. 450:566–569. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang J, Lei L, Pan J, Zhao C and Wen J:
Higher levels of serum interleukin-35 are associated with the
severity of pulmonary fibrosis and Th2 responses in patients with
systemic sclerosis. Rheumatol Int. 38:1511–1519. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Konishi J, Yamazaki K, Kinoshita I, Isobe
H, Ogura S, Sekine S, Ishida T, Takashima R, Nakadate M, Nishikawa
S, et al: Analysis of the response and toxicity to gefitinib of
non-small cell lung cancer. Anticancer Res. 25:435–441.
2005.PubMed/NCBI
|
|
24
|
Grande C, Villanueva MJ, Huidobro G and
Casal J: Docetaxel- induced interstitial pneumonitis following
non-small-cell lung cancer treatment. Clin Transl Oncol. 9:578–581.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Delaunay M, Cadranel J, Lusque A, Meyer N,
Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N,
Guisier F, et al: Immune-checkpoint inhibitors associated with
interstitial lung disease in cancer patients. Eur Respir J.
50:17000502017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brahmer JR, Lacchetti C, Schneider BJ,
Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner
JM, Ginex P, et al: National comprehensive cancer network.
Management of immune-related adverse events in patients treated
with immune checkpoint inhibitor therapy: American society of
clinical oncology clinical practice guideline. J Clin Oncol.
36:1714–1768. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haanen JBAG, Carbonnel F, Robert C, Kerr
KM, Peters S, Larkin J, Jordan K and ESMO Guidelines Committee:
Management of toxicities from immunotherapy: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 29
(Suppl 4):iv264–iv266. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Puzanov I, Diab A, Abdallah K, Bingham CO
III, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR,
et al: Society for immunotherapy of cancer toxicity management
working group. Managing toxicities associated with immune
checkpoint inhibitors: Consensus recommendations from the society
for immunotherapy of cancer (SITC) toxicity management working
group. J Immunother Cancer. 5:952017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
US Department of Health and Human
Services, National Institutes of Health, National Cancer Institute,
. Common Terminology Criteria for Adverse Events (CTCAE) Version
4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5×11.pdfMay
28–2009
|
|
30
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Friedman CF, Proverbs-Singh TA and Postow
MA: Treatment of the immune-related adverse effects of immune
checkpoint inhibitors: A review. JAMA Oncol. 2:1346–1353. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park H, Li Z, Yang XO, Chang SH, Nurieva
R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q and Dong C: A distinct
lineage of CD4 T cells regulates tissue inflammation by producing
interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miossec P and Kolls JK: Targeting IL-17
and TH17 cells in chronic inflammation. Nat Rev Drug Discov.
11:763–376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cosmi L, Liotta F and Annunziato F: Th17
regulating lower airway disease. Curr Opin Allergy Clin Immunol.
16:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wilson MS, Madala SK, Ramalingam TR,
Gochuico BR, Rosas IO, Cheever AW and Wynn TA: Bleomycin and
IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp
Med. 207:535–552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang J, Wang D, Wang L, Wang S, Roden AC,
Zhao H, Li X, Prakash YS, Matteson EL, Tschumperlin DJ and Vassallo
R: Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic
pulmonary fibrosis and rheumatoid arthritis-associated lung disease
support a direct role for IL-17A/IL-17RA in human fibrotic
interstitial lung disease. Am J Physiol Lung Cell Mol Physiol.
316:L487–L497. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dantas AT, Gonçalves SM, Pereira MC,
Gonçalves RS, Marques CD, Rego MJ, Pitta Ida R, Duarte AL and Pitta
MG: Increased IL-35 serum levels in systemic sclerosis and
association with pulmonary interstitial involvement. Clin
Rheumatol. 34:1621–1625. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Makkouk A and Weiner GJ: Cancer
immunotherapy and breaking immune tolerance: New approaches to an
old challenge. Cancer Res. 75:5–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Galati D, De Martino M, Trotta A, Rea G,
Bruzzese D, Cicchitto G, Stanziola AA, Napolitano M, Sanduzzi A and
Bocchino M: Peripheral depletion of NK cells and imbalance of the
Treg/Th17 axis in idiopathic pulmonary fibrosis patients. Cytokine.
66:119–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tomcik M, Zerr P, Palumbo-Zerr K,
Storkanova H, Hulejova H, Spiritovic M, Kodet O, Stork J, Becvar R,
Vencovsky J, et al: Interleukin-35 is upregulated in systemic
sclerosis and its serum levels are associated with early disease.
Rheumatology (Oxford). 54:2273–2282. 2015.PubMed/NCBI
|
|
42
|
Tanaka A and Sakaguchi S: Regulatory T
cells in cancer immunotherapy. Cell Res. 27:109–118. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma
YG, Wang XX, Liu HZ, Sun W and Hu ZW: Blocking IL-17A promotes the
resolution of pulmonary inflammation and fibrosis via
TGF-beta1-dependent and -independent mechanisms. J Immunol.
187:3003–3014. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kaiko GE, Horvat JC, Beagley KW and
Hansbro PM: Immunological decision making: How does the immune
system decide to mount a helper T-cell response? Immunology.
123:326–338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Munn DH: Blocking IDO activity to enhance
anti-tumor immunity. Front Biosci (Elite Ed). 4:734–745. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tosolini M, Kirilovsky A, Mlecnik B,
Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH,
Pagès F and Galon J: Clinical impact of different classes of
infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in
patients with colorectal cancer. Cancer Res. 71:1263–1271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
